Jed Ian Taxel Foundation for Rare Cancer Research Inc
Public records show a registered, tax-exempt organization in good standing.
What it says it does
To inspire and empower scientific breakthroughs, clinical trials and improved treatments which change lives and enable better outcomes for rare cancer patients and their families.
- Income
- $420,348
- Spending
- $270,754
- Spent on programs
- 71%
- Reserves
- 11.2 months of spending
- Largest source of income
- donations and private grants, 96%
- Employees
- 0
- Volunteers
- 40
- Highest pay
- $35,000, president/ceo
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Financial health
Strong: 93 out of 100. Higher than 68% of charities in its peer group (medical research, $250k to $1m).
Reserves
28 of 35Spendable reserves would cover 11.2 months of spending.
Debt
20 of 20It owes 14% of what it owns.
Living within its means
15 of 15Income exceeded spending by 36% of income.
Income trend
15 of 15Income rose 36% on the year before.
Spending floor
15 of 1571% of spending went to programs and raising each dollar of donations cost 7 cents.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Governance
Strong: 92 out of 100. Higher than 86% of charities in its peer group (medical research, $250k to $1m).
Independent board
25 of 2511 of 12 voting board members are independent.
Conflict of interest policy
15 of 15Has a written conflict of interest policy.
Whistleblower policy
8 of 8Has a written whistleblower policy.
Record keeping policy
7 of 7Has a written policy on keeping and destroying records.
Board minutes
5 of 5Keeps minutes of board meetings.
Board sees the tax return
10 of 10Gave the board a copy of this return before filing it.
Pay set independently
0 of 5Reports no independent review process for its chief executive's pay.
Independent check of accounts
12 of 15Its accounts were reviewed or compiled by an independent accountant, but not audited.
No reported misuse
10 of 10Reports no diversion of assets, excess benefits or loans to insiders.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Impact evidence
Describes programs. Its tax return describes what it does but we have found no measurable results in it.
Programs described in its return (1)
- $192,256 spent. The Alliance for Rare Cancers (ARC is a program of the Jedi Rare Cancer Foundation. Launched in 2024 as a collaborative consortium of researchers, clinicians, patients, and advocates across the rare cancer innovation system, ARC provides a venue for rare cancer stakeholders to co-create and implement large-scale collaborative partnerships across multiple rare tumor types to accelerate progress for patients. Following the completion of a strategic planning process in 2024 and pilot project development throughout 2025, ARC has moved from concept to execution. In partnership with Case Comprehensive Cancer Center (Case CCC) and the Rare Cancer Research Foundation (RCRF), ARC has initiated an ambitious two-year pilot program to create a scalable national platform for deep characterization of rare tumors. Supported by $1 million catalytic funding from the Chan Zuckerberg Initiative's Biohub and ongoing support from ARC founding sponsor the Jedi Rare Cancer Foundation, the collaboration aims to transform rare cancer research by combining advanced translational science with patient-powered data collection to accelerate the development of breakthrough therapies. The goal of this initiative is to ensure patients and physicians can access emerging research insights, navigate treatment options and directly benefit from scientific progress that translates research insights into care decisions. Jedi Rare Cancer Foundation funding continues to advance Phase Two of CURE: The Rare Cancer Initiative at Case Comprehensive Cancer Center by expanding deep tumor profiling, functional modeling, and translational testing of rare cancer patient biopsies. In development is an AI-based biomarker diagnostic tool that will deliver a scalable, cost-effective path from discovery to actionable better treatment approaches for rare cancer patients. This initiative represents the most comprehensive and innovative bedside-to-bench-to-bedside effort in rare cancer research to date and will catalyze innovation among research institutions to accelerate scientific discovery and transform rare cancer treatment.
Source: Form 990 for the year ending December 31, 2025, filed with the Internal Revenue Service. Rating method 2026.2. How we rate
Legitimacy checks
Is it registered with the IRS? Passed.
Listed in the IRS master file of tax-exempt organizations as a 501(c)(3) charitable organization.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Has the IRS revoked its tax-exempt status? Passed.
Not on the IRS automatic revocation list.
Source: Automatic revocation of exemption list, Internal Revenue Service, file dated November 6, 2026.
Are donations tax-deductible? Passed.
On the IRS list of organizations eligible to receive tax-deductible contributions.
Source: Publication 78 data: organizations eligible for tax-deductible contributions, Internal Revenue Service, file dated October 13, 2026.
Is it keeping up with its IRS filings? Passed.
Most recent return on file covers the year ending December 2025.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
How long has it been tax-exempt? Passed.
Recognized by the IRS since October 2021.
Source: Exempt Organizations Business Master File, Internal Revenue Service, file dated October 13, 2026.
Is it in good standing with state regulators? Passed.
Not on California's list of charities barred from soliciting. Other states are not yet checked.
Source: May Not Operate or Solicit for Charitable Purposes list, California Attorney General, Registry of Charities and Fundraisers, file dated November 4, 2026.
Ratings and checks are our reading of public records, using the published method. They are not a statement about anyone's honesty. If you work for this organization, you can send corrections or results, confirm you want gifts through Veridonate, or ask to be removed from giving.